Please login to the form below

Not currently logged in
Email:
Password:

Aveo Oncology

This page shows the latest Aveo Oncology news and features for those working in and with pharma, biotech and healthcare.

Relay Therapeutics strengthens team

Relay Therapeutics strengthens team

Bergstorm joins the biotech from Mersana Therapeutics, where he led the advancement of two oncology products. ... He has held roles for Keryx Biopharmaceutical, Algeta ASA and AVEO Oncology.

Latest news

  • NICE backs EUSA's RCC treatment Fotivda NICE backs EUSA's RCC treatment Fotivda

    cases. EUSA licenced Fotivda from Aveo Pharmaceuticals back in 2015, but although it has European approval in advanced renal cell carcinoma it failed to gain approval from the US Food and ... However, Aveo Oncology is looking to re-file Fotivda in the

  • Novartis licenses cancer support drug from Aveo Oncology Novartis licenses cancer support drug from Aveo Oncology

    Novartis licenses cancer support drug from Aveo Oncology. Swiss firm buys into drug to alleviate a wasting syndrome that is seen in chronic patients. ... Novartis is paying up to $326m to license rights to a drug developed by Aveo Oncology designed to

  • FDA turns down tivozanib for kidney cancer FDA turns down tivozanib for kidney cancer

    FDA turns down tivozanib for kidney cancer. Agency describes data provided by Aveo Oncology and Astellas as "uninterpretable". ... The US FDA has declined to approve Aveo Oncology and Astellas' kidney cancer drug tivozanib, saying the results of a

  • Regulatory struggles force Aveo to cut 140 jobs Regulatory struggles force Aveo to cut 140 jobs

    Aveo Oncology has announced it will cut 140 jobs based on expectations the US FDA will turn down its lead drug candidate tivozanib in renal cell carcinoma (RCC). ... bringing to a halt Aveo's plans for the drug in the condition. “

  • FDA committee turns down Aveo/Astellas’ cancer drug FDA committee turns down Aveo/Astellas’ cancer drug

    FDA committee turns down Aveo/Astellas’ cancer drug. Tivozanib unable to prove superiority to Bayer's Nexavar. ... Subject to regulatory approval, AVEO will lead commercialisation of tivozanib in North America and Astellas will lead commercialisation

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2016 Deal Watch March 2016

    Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory antibody for oesophageal cancer. ... Harvard University/ Merck &Co. Oncology – transcription regulating enzymes for leukaemia

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Research collaboration. 275. Definiens / AstraZeneca (through MedImmune). Tissue Phenomics Dx oncology biomarkers. ... Acquisition of voucher. 125. AVEO Oncology / Ophthotech Corporation. VEGF tyrosine kinase inhibitor tivozanib.

  • Pharma deals during February 2014 Pharma deals during February 2014

    In another termination of an oncology deal, Astellas exercised its right to terminate its collaboration with Aveo Oncology to develop the tyrosine kinase inhibitor, tivozanib, for “ strategic reasons”. ... Innate Pharma will prioritise development of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics